ARS Pharmaceuticals, Inc. — Director's Dealing 2025

Apr 8, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2025-04-07

Reporting Person: Shawver Laura (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-04-07	Common Stock	M	22509	$4.85	Acquired	232855	Direct
2025-04-07	Common Stock	M	27493	$4.85	Acquired	260348	Direct
2025-04-07	Common Stock	S	50002	$12.301	Disposed	210346	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-04-07	Stock Option (Right to Buy)	$4.85	M	22509	Disposed	2032-01-31	Common Stock (22509)	Direct
2025-04-07	Stock Option (Right to Buy)	$4.85	M	27493	Disposed	2032-01-31	Common Stock (27493)	Direct

Footnotes

F1: The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.

F2: The weighted average sale price for the transaction reported was $12.301 and the range of prices were between $12.0063 and $12.64. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3: Immediately exercisable.